Home Cart Sign in  
Chemical Structure| 108149-63-9 Chemical Structure| 108149-63-9

Structure of 108149-63-9

Chemical Structure| 108149-63-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 108149-63-9 ]

CAS No. :108149-63-9
Formula : C11H21NO4
M.W : 231.29
SMILES Code : O=C(N1C(C)(C)OC[C@H]1CO)OC(C)(C)C
MDL No. :MFCD06202686
InChI Key :DWFOEHLGMZJBAA-MRVPVSSYSA-N
Pubchem ID :11053464

Safety of [ 108149-63-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 108149-63-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 16
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 4
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 63.68
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

59.0 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.61
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.83
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.97
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.32
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.64
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.08

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.53
Solubility 6.78 mg/ml ; 0.0293 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.65
Solubility 5.16 mg/ml ; 0.0223 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.06
Solubility 20.3 mg/ml ; 0.0877 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.12 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.33

Application In Synthesis of [ 108149-63-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 108149-63-9 ]

[ 108149-63-9 ] Synthesis Path-Downstream   1~35

  • 3
  • [ 108149-63-9 ]
  • [ 95715-87-0 ]
YieldReaction ConditionsOperation in experiment
(S)-4-Formyl-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester Add dropwise over 2 hours a solution of pyridine sulfur trioxide (390 g, 2452.83 mmol) in dimethylsulfoxide (1600 mL) to a 6 C. maintained solution of <strong>[108149-63-9](S)-4-hydroxymethyl-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester</strong> (350 g, 1515.15 mmol) in diisopropylethylamine (1225 mL) with a dimethylsulfide trap. Over 30 minutes add water (1050 mL) keeping temperature below 15 C. Stir at 15 C. for 1.5 hours under a stream of nitrogen. Extract with ethyl acetate (5 L), wash with 5%-aqueous citric acid (2*1.5 L), saturated aqueous sodium chloride (2*1.5 L), dry (magnesium sulfate), filter, and concentrate to give the desired compound which is used in the next reaction without further purification (365 g). MS(ES): m/z=230 [M+H]
  • 4
  • [ 108149-60-6 ]
  • [ 108149-63-9 ]
YieldReaction ConditionsOperation in experiment
85% With sodium tetrahydroborate; In tetrahydrofuran; methanol; at 0℃; for 1.08333h;Reflux; To an ice-cold solution of 5 (3.0 g, 11.6 mmol) in anhydrousTHF (20 mL) was added NaBH4 (4.38 g, 116 mmol) with stirring. After 25 min, MeOH (8 mL) was slowly added. The mixture was warmed to reflux and stirred for 40 min.The resulting suspension was concentrated under reduced pressure and EtOAc (100 mL) was added. The organic layer was washed with water (2 X 50 mL), dried over Na2SO4, filtered and concentrated to give 6 as colorless oil (2.67 g,85% yield): [alpha]D21 +21.7 (c 1.2, CHCl3), lit: []D20 +23.8 (c1.2, CHCl3) [17]; IR v 3436, 2979, 2937, 2880, 1671, 1477,1456, 1388, 1365 cm-1; 1H NMR (200 MHz, CDCl3) (ppm): 3.92-3.47 (m, 6H, CH2OH, CH2O, OH, CHN), 1.47,1.41 (s, 15H, C(CH3)2, C(CH3)3); 13C NMR (50 MHz, CDCl3) (ppm): 153.68 (C=O), 93.83 (C), 80.92 (C(CH3)3),65.10, 64.24 (CH2O, CH2OH), 59.21 (CHN), 28.25(C(CH3)3), 27.04, 24.37 (CH3).
74% With methanol; lithium borohydride; In tetrahydrofuran; at 20℃; for 2h;Cooling with ice; (iS)-ter/-Butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (2). To an ice cold solution of commercially available 1 (35 g, 135 mmol) in THF MeOH (500 mL (95:5)) was added LiBH4 (5.9 g, 271 mmol) portionwise and the suspension was stirred for 2 h at RT. The reaction mixture was cooled and quenched with ice. Solvent was removed under reduced pressure, and water was added. The aqueous layer was extracted with EtOAc, concentrated and chromatographed (EtOAc:hexanes, 3:7) to yield 2 (23 g, 74 % yield).
74% With lithium borohydride; In tetrahydrofuran; methanol; at 20℃; for 2h;Cooling with ice; To an ice cold solution of commercially available 1 (35 g, 135 mmol) in THF/MeOH (500 mL (95:5)), was added LiBH4 (5.9 g, 271 mmol) portionwise and the suspension was stirred for 2 h at RT. The reaction mixture was cooled and quenched with ice. Solvent was removed under reduced pressure, and water was added. The aqueous layer was extracted with EtOAc, concentrated and chromatographed (EtOAc:hexanes, 3:7) to yield 2 (23 g, 74 % yield).
A solution of (i?)-3-tert-butyl 4-methyl 2,2-dimethyloxazolidine-3,4-dicarboxylate (5 g, 19.3 mmol) in anhydrous diethyl ether was chilled in an ice bath and 1 M LiAlH4 in diethyl ether (38 mL, 38.6 mmol) was added dropwise under an N2 atmosphere. The reaction was allowed to warm to room temperature with stirring overnight. The reaction was quenched by slowly adding saturated aqueous Na2SO4 (5 mL). The slurry was filtered through a pad of Celite.The Celite pad was rinsed with EtOAc and the solution was dried in vacuo to yield (S)-tert-buty4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate (2.77 g, 12 mmol) as a clear oil.[M+H] calc'd for CnH2INO4, 232; found, 232.
With sodium tetrahydroborate; lithium chloride; In tetrahydrofuran; ethanol; at 0 - 20℃; for 12.5h; After a mixture of NaBH4 (5.2 g, 139 mmol) and LiCl (5.9 g,139 mmol) in dry EtOH (30 mL) was stirred for 30 min at 0 C, compound20 (6.0 g, 23 mmol) dissolved in 15 mL of dry THF wasadded. The resulting mixture was warmed to room temperatureand stirred for 12 h. The precipitate was filtered over Celite andwashed with EtOH. The filtrate was then evaporated and partitionedbetween ethyl acetate and brine. After the aqueous layerwas extracted with ethyl acetate (5), the organic layer was driedover Na2SO4 and concentrated in vacuo to afford the intermediatealcohol as a yellow oil. To a reaction mixture of dry THF (100 mL)containing 11 g (42 mmol) of PPh3, 8.2 g (56 mmol) of phthalimide,and 6.6 g (28 mmol) of the yellow oil, 22.7 mL (40% in toluene,50 mmol) of diethyl azodicarboxylate dissolved in dry THF(20 mL) was added dropwise while stirring in an ice bath. After12 h at ambient temperature, the solvent was evaporated, and theresulting residue was purified by column chromatography (hexane/ethyl acetate = 3:1) to afford 21 as white crystals (5.4 g, 53%).

  • 5
  • [ 157604-46-1 ]
  • [ 108149-63-9 ]
  • [ 108149-63-9 ]
  • 7
  • [ 108149-63-9 ]
  • [ 102308-32-7 ]
  • 8
  • [ 20445-31-2 ]
  • [ 108149-63-9 ]
  • (R)-2,2-Dimethyl-4-((R)-3,3,3-trifluoro-2-methoxy-2-phenyl-propionyloxymethyl)-oxazolidine-3-carboxylic acid tert-butyl ester [ No CAS ]
  • 10
  • [ 198417-70-8 ]
  • [ 108149-63-9 ]
  • 11
  • [ 108149-63-9 ]
  • [ 106-96-7 ]
  • [ 472965-43-8 ]
  • 13
  • [ 121-71-1 ]
  • [ 108149-63-9 ]
  • 4-(3-acetylphenoxymethyl)-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester [ No CAS ]
  • 14
  • [ 108149-63-9 ]
  • [ 763122-66-3 ]
  • 15
  • [ 79069-54-8 ]
  • [ 108149-63-9 ]
  • 17
  • [ 505085-04-1 ]
  • [ 108149-63-9 ]
  • 18
  • [ 108149-63-9 ]
  • [ 97651-96-2 ]
  • 19
  • [ 108149-63-9 ]
  • [ 122225-54-1 ]
  • 20
  • [ 108149-63-9 ]
  • [ 763122-74-3 ]
  • 21
  • [ 108149-63-9 ]
  • (2''S)-1-(2''-tert-butoxycarbonylamino-2''-methoxycarbonyl-ethyl)-5-(β-D-glucopyranosyl)-1H-[1,2,3]triazole [ No CAS ]
  • 22
  • [ 108149-63-9 ]
  • [ 763122-86-7 ]
  • 23
  • [ 108149-63-9 ]
  • [ 763122-84-5 ]
  • 24
  • [ 108149-63-9 ]
  • [ 763122-85-6 ]
  • 25
  • [ 108149-63-9 ]
  • [ 763122-83-4 ]
  • 26
  • [ 108149-63-9 ]
  • [ 763122-76-5 ]
  • 27
  • [ 108149-63-9 ]
  • [ 763122-68-5 ]
  • 28
  • [ 108149-63-9 ]
  • [ 763122-88-9 ]
  • 29
  • [ 108149-63-9 ]
  • [ 763122-87-8 ]
  • 30
  • [ 108149-63-9 ]
  • [ 763122-77-6 ]
  • 31
  • [ 108149-63-9 ]
  • [ 763122-69-6 ]
  • 32
  • [ 108149-63-9 ]
  • (2''S)-1-(2''-tert-butoxycarbonylamino-2''-methoxycarbonyl-ethyl)-4-(2',3',4',6'-tetra-O-benzyl-β-D-glucopyranosyl)-1H-[1,2,3]triazole [ No CAS ]
  • 33
  • [ 108149-63-9 ]
  • (2''S)-1-(2''-tert-butoxycarbonylamino-2''-methoxycarbonyl-ethyl)-4-(2',3',4',6'-tetra-O-benzyl-β-D-galactopyranosyl)-1H-[1,2,3]triazole [ No CAS ]
  • 35
  • [ 108149-63-9 ]
  • (2''S)-1-(2''-tert-butoxycarbonylamino-2''-methoxycarbonyl-ethyl)-5-(2',3',4',6'-tetra-O-benzyl-β-D-galactopyranosyl)-1H-[1,2,3]triazole [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 108149-63-9 ]

Alcohols

Chemical Structure| 108149-65-1

A157912 [108149-65-1]

(S)-tert-Butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate

Similarity: 1.00

Chemical Structure| 714971-28-5

A132484 [714971-28-5]

(S)-4-Boc-(3-hydroxymethyl)morpholine

Similarity: 0.88

Chemical Structure| 473923-56-7

A196884 [473923-56-7]

4-Boc-(3-Hydroxymethyl)morpholine

Similarity: 0.88

Chemical Structure| 215917-99-0

A281465 [215917-99-0]

(R)-4-Boc-(3-Hydroxymethyl)morpholine

Similarity: 0.88

Chemical Structure| 152192-95-5

A109763 [152192-95-5]

tert-Butyl ethyl(2-hydroxyethyl)carbamate

Similarity: 0.78

Amides

Chemical Structure| 108149-65-1

A157912 [108149-65-1]

(S)-tert-Butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate

Similarity: 1.00

Chemical Structure| 714971-28-5

A132484 [714971-28-5]

(S)-4-Boc-(3-hydroxymethyl)morpholine

Similarity: 0.88

Chemical Structure| 473923-56-7

A196884 [473923-56-7]

4-Boc-(3-Hydroxymethyl)morpholine

Similarity: 0.88

Chemical Structure| 215917-99-0

A281465 [215917-99-0]

(R)-4-Boc-(3-Hydroxymethyl)morpholine

Similarity: 0.88

Chemical Structure| 102308-32-7

A131095 [102308-32-7]

(S)-3-Boc-2,2-dimethyloxazolidine-4-carboxaldehyde

Similarity: 0.88

Related Parent Nucleus of
[ 108149-63-9 ]

Oxazolidines

Chemical Structure| 108149-65-1

A157912 [108149-65-1]

(S)-tert-Butyl 4-(hydroxymethyl)-2,2-dimethyloxazolidine-3-carboxylate

Similarity: 1.00

Chemical Structure| 95715-87-0

A193576 [95715-87-0]

(R)-tert-Butyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate

Similarity: 0.88

Chemical Structure| 102308-32-7

A131095 [102308-32-7]

(S)-3-Boc-2,2-dimethyloxazolidine-4-carboxaldehyde

Similarity: 0.88

Chemical Structure| 139009-66-8

A290801 [139009-66-8]

(S)-N-Boc-2,2-dimethyloxazolidine-4-carboxylic Acid

Similarity: 0.85

Chemical Structure| 95715-86-9

A466943 [95715-86-9]

Methyl (R)-N-Boc-2,2-dimethyloxazolidine-4-carboxylate

Similarity: 0.84